Brief: NGM Bio Discloses Fourth Oncology Development Candidate, NGM831, An ILT3 Antagonist Antibody
23/08/2021 14:09
Aug 23 (Reuters) - NGM Biopharmaceuticals Inc NGM.O :
* NGM BIO DISCLOSES FOURTH ONCOLOGY DEVELOPMENT CANDIDATE,
NGM831,
AN ILT3 ANTAGONIST ANTIBODY, COINCIDING WITH PUBLICATION IN
CANCER IMMUNOLOGY RESEARCH
* NGM BIOPHARMACEUTICALS INC - NGM PLANS TO INITIATE
FIRST-IN-HUMAN TESTING OF NGM831 IN FIRST HALF OF 2022
Source text for Eikon: ID:nGNX7dB8kg
Further company coverage: NGM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on NGM Biopharmaceuticals
See all newsBrief: NGM Biopharmaceuticals Q4 Net Income USD -27.67 Million
Brief: NGM Bio Enters into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group
NGM Biopharmaceuticals Inc expected to post a loss of 39 cents a share - Earnings Preview
Brief: Ngm Biopharmaceuticals Says It Got Written Notice From Nasdaq Informing It Has Regained Compliance With Nasdaq Listing
Brief: NGM Bio Announces New Clinical Data From Ongoing Trial Of Ngm707 In Advanced Solid Tumors